Interpace Diagnostics Group, Inc. (61)

Browse by Contract Category

Contracts

Amendment to Security Agreement dated May 10, 2021 by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc (Filed With SEC on August 11, 2021)
Employment agreement entered into May 10, 2021, effective February 1, 2021, between Thomas Freeburg and the Company (Filed With SEC on May 11, 2021)
Lease Termination Notice to Meadows Landmark, LLC for the Companys laboratory facility at Meadows Office Complex, 201 Route 17 North, Rutherford, New Jersey, effective March 31,... (Filed With SEC on April 1, 2021)
Description of Securities (Filed With SEC on April 1, 2021)
Support Agreement, dated April 7, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc (Filed With SEC on October 19, 2020)
Termination Agreement, dated July 9, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc (Filed With SEC on October 19, 2020)
Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P (Filed With SEC on August 11, 2021)
Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership (Filed With SEC on August 11, 2021)
Security Agreement entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021, . Upon the request of the SEC, the Company agrees to furnish copies of the... (Filed With SEC on May 11, 2021)
Severance Agreement and General Release, dated January 31, 2021, by and between the Company and Fred Knechtel (Filed With SEC on February 4, 2021)
Separation and Consulting Agreement and General Release, dated November 23, 2020, between Jack E. Stover and Interpace Biosciences, Inc (Filed With SEC on November 25, 2020)
Employment Agreement, dated November 23, 2020, between Thomas W. Burnell and Interpace Biosciences, Inc (Filed With SEC on November 25, 2020)
Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma... (Filed With SEC on October 23, 2020)
Support Agreement, dated April 2, 2020, by and between 1315 Capital II, L.P. and Interpace Biosciences, Inc (Filed With SEC on October 19, 2020)
First Loan Modification Agreement, dated March 18, 2019, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc. (n/k/a Interpace Biosciences, Inc.), Interpace... (Filed With SEC on October 19, 2020)
Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan (Filed With SEC on June 26, 2020)
Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement (Filed With SEC on June 26, 2020)
Eleventh Amendment to Lease, effective as of June 1, 2020, by and between Southport Business Park Limited Partnership and Interpace Pharma Solutions, Inc (Filed With SEC on June 9, 2020)
Third Amendment to Lease, dated May 25, 2006, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Guaranty of Lease, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Southport Business Park Limited Partnership (Filed With SEC on April 22, 2020)
Assignment of Lease, dated July 15, 2019, by and between Cancer Genetics, Inc. and Interpace BioPharma, Inc (Filed With SEC on April 22, 2020)
Tenth Amendment to Lease, dated July 15, 2014, by and among Southport Business Park Limited Partnership, Gentris Corporation, and Gentris, LLC (Filed With SEC on April 22, 2020)
Ninth Amendment to Lease, dated November 7, 2012, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Eighth Amendment to Lease, dated July 27, 2011, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Seventh Amendment to Lease, dated October 26, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Sixth Amendment to Lease, dated June 3, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Fifth Amendment to Lease, dated June 15, 2009, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Fourth Amendment to Lease, dated December 20, 2007, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Letter Amendment, dated October 21, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Second Amendment to Lease, dated June 17, 2005, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Lease Agreement, dated June 12, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation (Filed With SEC on April 22, 2020)
Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc (Filed With SEC on April 22, 2020)
First Amendment to Lease, dated October 30, 2017, by and between Meadows Landmark LLC and Cancer Genetics, Inc (Filed With SEC on April 22, 2020)
Office Lease Agreement, dated October 9, 2007, by and between Meadows Office, L.L.C. and Cancer Genetics, Inc (Filed With SEC on April 22, 2020)
First Amendment, dated September 26, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation (Filed With SEC on April 22, 2020)
Amendment No. 8 to Lease, dated December 31, 2019, by and between WE 2 Church Street South LLC and Interpace Diagnostics Lab Inc (Filed With SEC on April 22, 2020)
Loan and Security Agreement, dated November 13, 2018, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, and Interpace... (Filed With SEC on April 22, 2020)
Description of Securities (Filed With SEC on April 22, 2020)
First Amendment to Amended and Restated Employment Agreement, dated January 29, 2020, by and between Interpace Biosciences, Inc. and Jack E. Stover (Filed With SEC on January 31, 2020)
Severance and Consulting Agreement and General Release, dated January 29, 2020, by and between Interpace Biosciences, Inc. and James Early (Filed With SEC on January 31, 2020)
Employment Agreement, dated as of January 29, 2020, by and between Interpace Biosciences, Inc. and Fred Knechtel (Filed With SEC on January 31, 2020)
Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee (Filed With SEC on January 17, 2020)
Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership (Filed With SEC on January 17, 2020)
Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (included as Exhibit A to the Securities Purchase and Exchange... (Filed With SEC on January 14, 2020)
Interpace Biosciences, Inc. 2019 Equity Incentive Plan (Filed With SEC on November 14, 2019)
Form of Stock Option Grant Notice and Stock Option Agreement under the Interpace Biosciences, Inc. 2019 Equity Incentive Plan (Filed With SEC on November 14, 2019)
Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Interpace Biosciences, Inc. 2019 Equity Incentive Plan (Filed With SEC on November 14, 2019)
Interpace Biosciences, Inc. Employee Stock Purchase Plan (Filed With SEC on November 14, 2019)
Equity Distribution Agreement, dated September 20, 2019, by and between Interpace Diagnostics Group, Inc. and Oppenheimer & Co. Inc (Filed With SEC on September 20, 2019)
Securities Purchase Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)
Transition Services Agreement, dated July 15, 2019, by and between Interpace BioPharma, Inc. and Cancer Genetics, Inc (Filed With SEC on July 19, 2019)
Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
Investor Rights Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Form of Voting Agreement (Filed With SEC on July 19, 2019)
Employment Separation Agreement between Interpace Diagnostics, LLC and Gregory Richard, effective as of March 25, 2015 (Filed With SEC on March 21, 2019)
Underwriting Agreement, dated as of January 25, 2019, by and between Interpace Diagnostics Group, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 29, 2019)
Form of Underwriter Common Stock Purchase Warrant (Filed With SEC on January 29, 2019)